FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesForecasting
Topics: EAP, Forecasting / Planning
Video
Members
GCSG 2024 US Conference Slides
Topic: Conference
Presentation
Members
Leadership Lessons for Re-Entry
Topics: Leadership, Management
Webinar
Free
